Scisparc announces positive results for mitocarex bio with its drug discovery platform

Mitocarex bio has met its second milestone as part of its joint venture agreement with the company tel aviv, israel, nov. 27, 2023 (globe newswire) -- scisparc ltd. (nasdaq: sprc) ("company" or "scisparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced that mitocarex bio ltd.
SPRC Ratings Summary
SPRC Quant Ranking